About FURVENT FURVENT is a global, pivotal 3 arm Phase 3 clinical trial of firmonertinib in first-line non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations being ...

LCGC International spoke to Evelyn Rampler of the Department of Analytical Chemistry at the University of Vienna about the ...

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 ...

Asia Broadband - Phase 2 Production Line Processing Plant Equipment Received From China and On Track for Build-Out ...

Abstract Summary Pharmacological enhancement of endoplasmic reticulum (ER) proteostasis is an attractive strategy to mitigate pathology linked to etiologically-diverse protein misfolding diseases.

Naveen Jindal-promoted Jindal Steel Duqm — the Oman-based entity — plans to operationalise the first phase of its hydrogen-enabled green steel plant in December 2028.

Dalmia Bharat targets 130 mtpa capacity, open to organic growth and acquisitions Phase II expansion to further reinforce the company’s position as a pan-India pure-play cement player ...

Scotiabank believes Danaher is on track to accelerate its growth profile over the next 12-18 months, potentially reaching its long-range plan of high single-digit top-line compound annual growth rate.

Our data shows many families explore tattoo preservation to keep a loved one’s skin art visible after death rather than lose ...